About Nurix Therapeutics (NRIX)

The current price per share for Nurix Therapeutics (NRIX) is $23.33. The stock has seen a price change of -$1.11 recently, indicating a -4.54% change. This reflects the stock's recent market performance and investor sentiment.

For Nurix Therapeutics (NRIX), the 52-week high is $26.12, which is 11.97% from the current price. The 52-week low is $4.22, the current price is 452.84% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

Nurix Therapeutics (NRIX) has shown an average price growth of 0.41% over the past three years. It has received a score of 31 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Nurix Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

As of the latest data, Nurix Therapeutics (NRIX) has a year-to-date price change of 128.28%. Over the past month, the stock has experienced a price change of 10.1%. Over the last three months, the change has been 42.87%. Over the past six months, the figure is 48.98%.

Nurix Therapeutics (NRIX) has a net income of -$143.95M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 82.26% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -401.42% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $76.99M, with a revenue growth rate of 99.31%, providing insight into the company's sales performance and growth. The gross profit is $63.33M. Operating income is noted at -$155.06M. Furthermore, the EBITDA is -$172.24M.

Nurix Therapeutics (NRIX) has a market capitalization of $1.57B. The average daily trading volume is 540.16K, indicating the stock's liquidity and investor engagement.